DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083

-- Increases Total Number of DelMar Patents Covering VAL-083 to Three US Patents and One International Patent --

13 Jan, 2015, 08:00 ET from DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 13, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company") today announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)". 

"This new patent allowance is representative of our intellectual property strategy aimed at protecting and enhancing the value of VAL-083," stated Jeffrey Bacha, DelMar's president and CEO.  "This patent provides a broad portfolio of new claims around VAL-083, a drug candidate that showed promise against multiple cancers in previous clinical trials sponsored by the U.S. National Cancer Institute (NCI).  These modern analytical methods are important in assuring the quality and purity of our drug product as we advance toward registration trials in the United States and seek to unlock the global commercial potential of VAL-083." 

DelMar will provide an update on the Company's ongoing Phase I/II glioblastoma clinical trial with VAL-083 during DelMar's presentation at the Biotech Showcase Conference tomorrow at 1:45 PM Pacific Time.  The presentation will be webcast and a live link will be available on the Company's website at www.delmarpharma.com

About VAL-083
VAL-083 is a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action.  In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute, VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia.  VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.  As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).  DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme.

About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.  The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.  DelMar's scientific presentations can be viewed on the company's website at www.delmarpharma.com

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO  (604) 629-5989 or Amato and Partners, LLC Investor Relations, admin@amatoandpartners.com 

 

 

SOURCE DelMar Pharmaceuticals, Inc.



RELATED LINKS

http://www.delmarpharma.com